Exhibits alpha-actinin binding activity; protein domain specific binding activity; and spectrin binding activity. Predicted to be involved in several processes, including JNK cascade; myoblast fusion; and positive regulation of actin filament polymerization. Localizes to several cellular components, including membrane raft; plasma membrane; and slit diaphragm. Biomarker of end stage renal disease; kidney failure; membranous glomerulonephritis; and nephrotic syndrome. Human ortholog(s) of this gene implicated in nephrotic syndrome type 1. Orthologous to human NPHS1 (NPHS1 adhesion molecule, nephrin); INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine.
triptolide inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 protein], Y 27632 inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 mRNA]
5-hydroxymethylfurfural co-treated with 3, 4-dideoxyglucosone co-treated with Glyoxal co-treated with Methylglyoxal cotreated with 3-deoxyglucosone co-treated with Formaldehyde co-treated with acetaldehyde decreases expression of Nphs1 protein in kidneys
acetovanillone inhibits the reaction [Homocysteine results in decreased expression of NPHS1 mRNA], acetovanillone inhibits the reaction [Homocysteine results in decreased expression of NPHS1 protein]
[Flame Retardants co-treated with pentabromodiphenyl ether co-treated with decabromobiphenyl ether co-treated with hexabromocyclododecane] results in increased expression of NPHS1 mRNA
AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of NPHS1 mRNA], Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of NPHS1 mRNA]
diphenyleneiodonium inhibits the reaction [Homocysteine results in decreased expression of NPHS1 mRNA], diphenyleneiodonium inhibits the reaction [Homocysteine results in decreased expression of NPHS1 protein]
Filipin inhibits the reaction [Homocysteine results in decreased expression of NPHS1 mRNA], Filipin inhibits the reaction [Homocysteine results in decreased expression of NPHS1 protein]
[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS1 mRNA, CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS1 mRNA]
Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein], Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]
Mercuric Chloride promotes the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 protein], Puromycin Aminonucleoside promotes the reaction [Mercuric Chloride results in decreased expression of NPHS1 mRNA]
methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in decreased expression of NPHS1 mRNA], methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in decreased expression of NPHS1 protein]
Mycophenolic Acid inhibits the reaction [Streptozocin results in decreased expression of NPHS1 mRNA], Mycophenolic Acid inhibits the reaction [Streptozocin results in decreased expression of NPHS1 protein]
Prednisone inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein], Prednisone inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]
procyanidin B2 inhibits the reaction [Streptozocin results in increased expression of NPHS1 mRNA], procyanidin B2 inhibits the reaction [Streptozocin results in increased expression of NPHS1 protein]
trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA], trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein]
Valsartan inhibits the reaction [Streptozocin results in decreased expression of NPHS1 mRNA], Valsartan inhibits the reaction [Streptozocin results in decreased expression of NPHS1 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
